Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOURMALINE: Durvalumab plus gemcitabine-based chemotherapy in advanced biliary tract cancer
jRCT2061230037Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of durvalumab in biliary cancer, intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA) and 2 more, sponsored by AstraZeneca. Primary endpoint: Number of participants with Grade 3 or 4 possibly related adverse event (PRAE). Started Sep 2023; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)gallbladder cancerAmpullary cancer (AC)
Beyond the preview
Go deeper on jRCT2061230037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230037.